ImmunoCellular Therapeutics Ltd Revenue and Competitors

USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ImmunoCellular Therapeutics Ltd's estimated annual revenue is currently $2M per year.(i)
  • ImmunoCellular Therapeutics Ltd's estimated revenue per employee is $155,000

Employee Data

  • ImmunoCellular Therapeutics Ltd has 13 Employees.(i)
  • ImmunoCellular Therapeutics Ltd grew their employee count by 0% last year.

ImmunoCellular Therapeutics Ltd's People

NameTitleEmail/Phone
1
CEO/PresidentReveal Email/Phone
2
VP Finance/Principal Accounting OfficerReveal Email/Phone
3
Corporate ParalegalReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$9.1M59-9%N/AN/A
#10
$16.6M1073%N/AN/A
Add Company

What Is ImmunoCellular Therapeutics Ltd?

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellular’s pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient’s hematopoietic stem cells to generate antigen-specific cancer-killing T-cells.

keywords:N/A

N/A

Total Funding

13

Number of Employees

$2M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.9M13N/AN/A
#2
$1.1M13N/AN/A
#3
$1.1M13N/AN/A
#4
$1.1M13N/AN/A
#5
$2.1M13N/AN/A